Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Phil E. Thuma"'
Autor:
Brooke E Nichols, Charles A B Boucher, Janneke H van Dijk, Phil E Thuma, Jan L Nouwen, Rob Baltussen, Janneke van de Wijgert, Peter M A Sloot, David A M C van de Vijver
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e59549 (2013)
BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infections are averted at the lowest cost is unknown. We determined the impact
Externí odkaz:
https://doaj.org/article/a297d0d1da44426e872bb1a31c434783
Autor:
Brooke E Nichols, Rob Baltussen, Phil E. Thuma, Janneke H. van Dijk, Jan L. Nouwen, Charles A. Boucher, David A. M. C. van de Vijver
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes
Jaids. Journal of Acquired Immune Deficiency Syndromes, 66(2), 221-228. Lippincott Williams & Wilkins
JAIDS : Journal of Acquired Immune Deficiency Syndromes, 66, 221-8
JAIDS : Journal of Acquired Immune Deficiency Syndromes, 66, 2, pp. 221-8
JAIDS Journal of Acquired Immune Deficiency Syndromes; Vol
Jaids. Journal of Acquired Immune Deficiency Syndromes, 66(2), 221-228. Lippincott Williams & Wilkins
JAIDS : Journal of Acquired Immune Deficiency Syndromes, 66, 221-8
JAIDS : Journal of Acquired Immune Deficiency Syndromes, 66, 2, pp. 221-8
JAIDS Journal of Acquired Immune Deficiency Syndromes; Vol
Item does not contain fulltext BACKGROUND: Earlier antiretroviral therapy initiation and pre-exposure prophylaxis (PrEP) prevent HIV, although at a substantial cost. We use mathematical modeling to compare the cost-effectiveness and economic affordab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6852ec95e85d71430467d427e245e778
https://hdl.handle.net/2066/137704
https://hdl.handle.net/2066/137704
Autor:
Jan L. Nouwen, Charles A. Boucher, Janneke van de Wijgert, David A. M. C. van de Vijver, Janneke H. van Dijk, Brooke E Nichols, Peter M. A. Sloot, Rob Baltussen, Phil E. Thuma
Publikováno v:
PLoS One (print), 8(3):e59549. Public Library of Science
PLoS One, 8
PLoS One, 8, 3
PLoS ONE; Vol 8
PLoS ONE, Vol 8, Iss 3, p e59549 (2013)
PLoS ONE, 8(3):e59549. Public Library of Science
PLoS ONE
PLoS One, 8
PLoS One, 8, 3
PLoS ONE; Vol 8
PLoS ONE, Vol 8, Iss 3, p e59549 (2013)
PLoS ONE, 8(3):e59549. Public Library of Science
PLoS ONE
Contains fulltext : 118224.pdf (Publisher’s version ) (Open Access) BACKGROUND: Pre-exposure prophylaxis (PrEP) with tenofovir and emtricitabine effectively prevents new HIV infections. The optimal scenario for implementing PrEP where most infectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85cdcc0d1064120fc5ee36226ea034d2
https://hdl.handle.net/11245/1.392712
https://hdl.handle.net/11245/1.392712
Autor:
Nichols, Brooke E.1 b.nichols@erasmusmc.nl, Boucher, Charles A. B.1, van Dijk, Janneke H.2 d.vandevijver@erasmusmc.nl, Thuma, Phil E.2, Nouwen, Jan L.1, Baltussen, Rob3, van de Wijgert, Janneke4, Sloot, Peter M. A.5, van de Vijver, David A. M. C.1
Publikováno v:
PLoS ONE. Mar2013, Vol. 8 Issue 3, p1-10. 10p.
Autor:
Nichols, Brooke E., Baltussen, Rob, van Dijk, Janneke H., Thuma, Phil E., Nouwen, Jan L., Boucher, Charles A.B., van de Vijver, David A.M.C.
Publikováno v:
JAIDS: Journal of Acquired Immune Deficiency Syndromes; 6/1/2014, Vol. 66 Issue 2, p221-228, 8p